Effects of β-caryophyllene, A Dietary Cannabinoid, in Animal Models of Drug Addiction

Background: beta-caryophyllene (BCP) is a natural bicyclic sesquiterpene found in Cannabis and other plants. BCP is currently used as a food additive, although pharmacological studies suggest its potential therapeutic application for the treatment of certain brain disorders. The mechanisms of action of BCP remain uncertain, possibly including full agonism at the cannabinoid CB2 receptor (CB2R). Objective: The study aims to investigate BCP's potential as a new drug for the treatment of substance use disorders by reviewing preclinical studies with animal models. Results: BCP has been investigated in behavioral paradigms, including drug self-administration, conditioned place preference, and intracranial self-stimulation; the drugs tested were cocaine, nicotine, alcohol, and methamphetamine. Remarkably, BCP prevented or reversed behavioral changes resulting from drug exposure. As expected, the mechanism of action entails CB2R activation, although this is unlikely to constitute the only molecular target to explain such effects. Another potential target is the peroxisome proliferator-activated receptor. Conclusion: Preclinical studies have reported promising results with BCP in animal models of substance use disorders. Further research, including studies in humans, are warranted to establish its therapeutic potential and its mechanisms of action.

Automated summary

This study investigates the potential of beta-caryophyllene (BCP) as a new drug for the treatment of substance use disorders in animal models. The results show that BCP can prevent or reverse behavioral changes resulting from drug exposure. The mechanism involves activation of the CB2 receptor and potentially other targets. Further research, including studies in humans, is needed to establish its therapeutic potential and mechanisms of action.